Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Summit Announces Agreement For a Fundraising of Approximately $50 Million
Details : Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 10, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Reset All
